Nichole Tucker

The targeted alpha therapy, FPI-1966, has been dosed for the first time in a phase 1/2 study of patients with advanced solid tumors that express FGFR3.

In an interview with Targeted Oncology, Eunice S. Wang, MD, discussed the growing use of menin inhibitors in acute myeloid leukemia, and clinical trial research further supporting the treatment strategy.

In the CodeBreaK 200 clinical trial, progression-free survival was extended with sotorasib treatment in patients with KRAS G12C-mutated non–small cell lung cancer vs standard of care chemotherapy.

In the interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the FDA approval of pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. He also discussed the FIGHT-203 trial, and possibilities for pemigatinib in the future.

No significant survival differences were shown between 2 high-dose regimens for newly diagnosed multiple myeloma. However, certain prognostic factors may improve or decrease survival.

During the 2022 Debates and Didactics in Hematology and Oncology conference, Bassel Nazha, MD, MPH and Jacqueline T. Brown, MD, debated on adjuvant vs neoadjuvant systemic therapy for patients with upper tract urothelial cancer.

Findings from.the phase 1/2 IMAGINE have led the FDA to approve ibrutinib for select pediatric and young adult patients with chronic graft-versus-host disease.

Following an FDA investigational new drug application and protocol approval, the phase 2 study of AMP-270 and rintatolimod in patients with advanced pancreatic cancer has begun.

Treatment with CD30 chimeric antigen receptor T-cell therapy combined with a monoclonal antibody has begun in the phase 1b ACTION study of patients with relapsed or refractory classical Hodgkin lymphoma.

The TakeAim Lymphoma study will continue to evaluate emavusertib with or without ibrutinib in patients with various types of lymphoma after a 4 1/2-month partial clinical hold placed by the FDA.

In an interview with Targeted Oncology, Brandon Sheffield, MD, discussed relevant biomarkers for testing in patients with non–small cell lung cancer, and the cost-effectiveness of single-gene test vs next-generation sequencing.

Patients with either breast cancer, endometrial cancer, or ovarian cancer have started treatment with XMT-1660 in a phase 1 clinical trial.

Results from MOMENTUM and other phase 3 studies will be reviewed by the FDA as the regulatory body considers approval of momelotinib for patients with myelofibrosis and anemia.

In an interview with Targeted Oncology, Cary Gross, MD, discussed retrospective research that revealed testing and treatment disparities among Medicaid beneficiaries with advanced non–small cell lung cancer, and the steps needed to improve outcomes for the patient population.

By April 2023, the FDA plans have a decision on the approval application for polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone as an option for treatment-naïve diffuse large B-cell lymphoma.

Findings from the phase 2 DESTINY-Breast02 show that trastuzumab deruxtecan improves both progression-free and overall survival in patients with HER2-positive unresectable and/or metastatic breast cancer.

In season 3, episode 7 of Targeted Talks, John Nakayama, MD, discusses updates in the endometrial cancer treatment landscape.

Accelerated approval has been granted to trastuzumab deruxtecan for patients with HER2-positive unresectable or metastatic non-small cell lung cancer based on positive results from DESTINY-Lung02.

An accelerated approval by the FDA for capmatinib has be converted to a regular approval based on new data from adults patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping.

Positive findings from the phase 3 EMERALD study led to a new drug application for elacestrant as treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The FDA has granted the application priority review.

In an interview with Targeted Oncology, Jennifer Moss, MD, discussed health-related quality-of-life in older, rural vs urban patients with cancer and survivors. She also explained factors contributing to the disparity and how to improve outcomes for the population.

Interim findings from the phase 1 DELLphi-300 shows that tarlatamab may induce responses in heavily-pretreated patients with small cell lung cancer.

Results from the interim analysis of phase 3 KarMMa-3 study indicate improvement in progression-free survival with idecabtagene vicleucel compared with standard combination regimens, as well as better responses.

High-dose REGN5678 combined with cemiplimab shows preliminary response elicitation in patients with metastatic castration-resistant prostate cancer.

Frontline treatment with ibrutinib, bendamustine, and rituximab showed a prolongation in progression-free survival along with a good response rate in older patients with mantle cell lymphoma.

The phase 3 RESILIENT trial of irinotecan liposomal injection vs topotecan failed to meet its primary end point of overall survival in patients with previously treated small cell lung cancer.

In the phase 3 IMscin001 clinical trial, the use of subcutaneous atezolizumab demonstrated similar efficacy, safety, and pharmacokinetics compared with intravenous atezolizumab in patients with immunotherapy-naïve locally advanced or metastatic non—small cell lung cancer.

The phase 3 INTERLINK-1 study of monalizumab and cetuximab as treatment of recurrent or metastatic squamous cell carcinoma of the head and neck has been discontinued. The study did not meet its efficacy goal.

In an interview with Targeted Oncology, Lori Wirth, MD, discussed the evolving treatment landscape for NTRK fusion-positive thyroid cancers.

In the phase 3 CheckMate-914 clinical trial, the combination of nivolumab and ipilimumab did not achieve its primary end point of improvement in disease-free survival compared with the placebo control.